UK ABPI Suspends Novo Nordisk Over Code Breach
Novo Nordisk has been given a two-year suspension from membership of the Association of the British Pharmaceutical Industry for breaching the association’s code of practice.
You may also be interested in...
Wegovy Wins English Funding For Weight Loss As Novo Deals With Supply Issues
Unprecedented demand for Wegovy in the US, together with issues experienced at the contract manufacturing site that resulted in supply shortages, led to Novo Nordisk having to wait some time for NICE to publish its final recommendation for the drug’s use on the National Health Service in England.
ABPI’s 6.88% Rebate Proposal ‘Completely Unaffordable,’ Says UK Health Dept
Plans for a new kind of drug pricing scheme put forward by the UK ABPI are intended to put the life sciences sector “back on the path for future growth,” the association says.
ABPI President Steps Down Amid Novo Nordisk Code Of Practice Breach
The president of the Association of the British Pharmaceutical Industry and UK head of Novo Nordisk, Pinder Sahota, has resigned from the role at the association after the company breached the ABPI's Code of Practice.